Public Joint-Stock Company Pharmsynthez, a pharmaceutical company, researches, manufactures, and distributes officinal and generic active pharmaceutical ingredients in Russia, Europe, the United States, and CIS countries. The company offers officinal medicines, including Neovir, Segidrin, Glaumax, Vazostenon, Neostim, Fludarabel, Fenazide, Fenasid, and Penkrofton that are used in oncology, gynecology, treatment of immune deficiencies, and tuberculosis. Public Joint-Stock Company Pharmsynthez was founded in 1996 and is based in St. Petersburg, Russia.
Frequently asked questions
What sector does Pharmsynthez (LIFE) operate in?
Pharmsynthez belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Pharmsynthez (LIFE) current stock price?
As of the latest data, Pharmsynthez stock price is RUB 1.65, with a previous close of RUB 1.65.
What is Pharmsynthez (LIFE) current market capitalization?
Pharmsynthez market cap is approximately 724.45 million.
Does Pharmsynthez (LIFE) pay dividends?
No. Pharmsynthez does not pay a dividend.
What is Pharmsynthez (LIFE) beta (volatility) score?
Pharmsynthez has a beta of 1.302, suggesting it is more volatile than the market.